Is there a patent crisis? It depends on whom you ask. Neither Europe nor China seem to see more than relatively minor difficulties in particular areas, although there are some issues looming in patent-heavy sectors such as...more
In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc, the United States Supreme Court held that a prior public sale of a patented product could destroy the novelty of a patent for that product even though there was no...more
1/30/2019
/ America Invents Act ,
Appeals ,
Assignment of Inventions ,
Confidentiality Agreements ,
Helsinn Healthcare SA v Teva Pharmaceuticals USA Inc ,
Inventions ,
On-Sale Bar ,
Patent Applications ,
Patent Infringement ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Public Use ,
Reaffirmation ,
Reversal ,
SCOTUS ,
Section 102 ,
Third-Party Relationships
On July 20 in Saint Regis Mohawk Tribe, Allergan, Inc. v. Mylan Pharmaceuticals Inc., a panel of the U.S. Court of Appeals for the Federal Circuit (Dyk, Moore and Reyna JJ) held that Native American (“Indian”) Tribes do not...more
7/27/2018
/ Allergan Inc ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Mylan Pharmaceuticals ,
Native American Issues ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Sovereign Immunity ,
Tribal Governments ,
USPTO
In its decision of July 12, 2017 in Actavis v. Eli Lilly, the Supreme Court of the United Kingdom for the first time formally adopted the concept of a doctrine of equivalents when considering what constituted an infringement...more
3/19/2018
/ Actavis Inc. ,
Appeals ,
Doctrine of Equivalents ,
Eli Lilly ,
EU ,
Extraterritoriality Rules ,
Indirect Infringement ,
Intellectual Property Protection ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
UK ,
UK Supreme Court
On June 12, 2017, in a unanimous decision authored by Justice Thomas in Amgen Inc. v. Sandoz Inc., the United States Supreme Court considered the complex statutory scheme that attempts to expedite resolution of patent...more
8/21/2017
/ Amgen ,
Biologics ,
Biosimilars ,
BPCIA ,
Commercial Marketing ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Intellectual Property Protection ,
Life Sciences ,
Patent Dance ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Sandoz ,
Sandoz v Amgen ,
SCOTUS
2016 has been a year of IP changes and these changes have had an effect upon biotechnology as well as trade secrets.
Patents: Will the U.S. Supreme Court Grant Cert. In Ariosa v. Sequenom?
Ariosa v. Sequenom was...more
6/7/2016
/ Biotechnology ,
Defend Trade Secrets Act (DTSA) ,
DNA ,
European Patent Office ,
Myriad-Mayo ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Personalized Medicine ,
Pharmaceutical Patents ,
Popular ,
Sequenom ,
USPTO
This year the IP world will be brimming with changes, the largest of which will take place in the European Union. Sweeping reforms in EU trademark law will be implemented in March as well as the likelihood of the Unitary...more
2/24/2016
/ Apple v Samsung ,
Brazil ,
Canada ,
China ,
Copyright ,
Cuozzo Speed Technologies v Lee ,
Design Patent ,
Eli Lilly ,
EU ,
European Court of Justice (ECJ) ,
FRAND ,
Halo v Pulse ,
Japan ,
Lanham Act ,
Lexmark ,
Madrid Protocol ,
Patent Litigation ,
Pharmaceutical Patents ,
Redskins ,
SCOTUS ,
Standard Essential Patents ,
Trade Secrets ,
Trademark Litigation ,
UK ,
Unitary Patent ,
World Intellectual Property Organisation